Publication | Closed Access

Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study

Cancer ImmunosurveillanceAnti-ctla-4 AntibodiesMedicineMelanomaImmunologyTumor ImmunityImmune Checkpoint InhibitorReal-world EfficacyAnti-pd-1 AntibodyImmunotherapyOncologyRadiation OncologySkin Cancer